Palisade Bio, Inc. (NASDAQ:PALI) Receives $16.00 Consensus Target Price from Brokerages

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $13.25.

Several research firms have commented on PALI. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Piper Sandler started coverage on shares of Palisade Bio in a report on Monday, December 29th. They issued an “overweight” rating and a $25.00 price target for the company. Wall Street Zen lowered Palisade Bio from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Finally, Citigroup reissued a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th.

Palisade Bio Price Performance

Shares of PALI opened at $1.85 on Friday. The stock has a market capitalization of $275.65 million, a price-to-earnings ratio of -0.87 and a beta of 1.58. Palisade Bio has a 1 year low of $0.53 and a 1 year high of $2.64. The business’s 50 day simple moving average is $1.87 and its 200-day simple moving average is $1.57.

Institutional Trading of Palisade Bio

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC bought a new stake in Palisade Bio in the fourth quarter worth $28,318,000. Commodore Capital LP purchased a new stake in shares of Palisade Bio in the fourth quarter valued at $26,896,000. Janus Henderson Group PLC purchased a new stake in shares of Palisade Bio in the fourth quarter valued at $24,822,000. RA Capital Management L.P. bought a new stake in shares of Palisade Bio in the 4th quarter worth about $16,742,000. Finally, Eversept Partners LP purchased a new position in shares of Palisade Bio during the 4th quarter worth about $12,670,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.